1. scil Artisan Coral BioNet Scil Investment Holding GmbH Scil Technology Holding GmbH Scil Animal Care Scil Animal Care Scil Diagnostics Scil Diagnostics Scil Pharma- ceuticals Scil Pharma- ceuticals Scil Protein Scil Protein BioNet Laboratories Asia Diagnostics BioNet Laboratories Asia Diagnostics SCIL Finance Holding GmbH Stefan Engelhorn 20 %80 %

2. scil Scil Technology Holding Use niches in Life Science to develop, manufacture and market diagnostics and therapeutics Use investment possibilities to synergize the existing operative business Bridge the gap between VC funded companies and big pharma by using professional industrial development know how Create profit along the value chain for our partners and ourselves

3. scil Scil Technology Holding: Objectives Short term (3 years): Focus on industrial development know how and use existing network in diagnostics and therapeutics to acquire projects and to generate short term cash flow Medium term (3 - 6 years): Focus on technologies around proteins. Use know how in protein technology for own developments and as service. Collaborate with partners for co-developments and co-marketing Long term (> 6 years): Use the synergistic potential of diagnostic and therapeutic activities to create integrated solutions for more efficient treatments in niche indications

4. scil Scil Technology Holding: Competencies An one year old privately own company which is actively involved in the development and marketing of diagnostics and therapeutics Diagnostics proprietary immunoassay technology and data transfer concept innovative reagent packaging concept sales organizations in Europe, US, Canada and Asia (Singapore) products in food testing Therapeutics focus on the development of therapeutic proteins according a synergistic partnership concept anti-L-selectin (partner PDL) for polytrauma  clinical phase I completed research and development activities in the field of intensive care, skin disorders, wound healing and hard tissue repair Use the synergistic potential of diagnostics and therapeutics to create integrated health care concepts for niche indications

5. scil Scil Group: Management Team S. Engelhorn, Ph.D., M.D. G. Schumacher, Ph.D. J. Bornemann C. Dony, Ph.D. J. Feuerstein, Ph.D. R. Schenk, Ph.D. U. Martin, M.D. CEO of Scil Finance Holding. President of Scil Technology Holding. Member and chairman of several trusts CEO of Scil Technology Holding. 20 years of industrial experience in diagnostics and therapeutics. Former head of R&D at BM/Roche Vice President, DFO of Scil Technology Holding. Former at KPMG, tax consultant and commercial director at Gebr. März AG and Leonard Moll AG. Vice President, Research and Development of Scil Technology Holding. Former head of musculoskeletal disorders at BM/Roche, scientist at Genentech Inc. CEO of Scil Diagnostics. Former global strategic project planning at BM/ Roche. Focus: marketing, PSO organization management, partnership management CEO of Scil Diagnostics. Former head of system development and leader project lab diagnostics at BM/Roche. Focus: system and technology concepts and implementation CEO of Scil Pharmaceuticals. Former head of pharmacology and cardiovascular research at BM/Roche and senior scientist at Hoechst

6. scil Scil Pharmaceuticals: Mission Scil Pharmaceuticals is a young privately owned company with the mission to use professional industrial drug-development know how to develop, manufacture and market innovative bio-pharmaceuticals

7. scil Scil Pharmaceuticals: Corporate Profile  Founded in May 1999  Privately owned company  Subsidiary of Scil Technology Holding GmbH  Employees: 17 people, 50 people mid of 2000  Focus: - development of innovative protein pharmaceuticals - focus on niche indications - protein technology services

8. scil Scil Pharmaceuticals: Facilities Munich: Development of protein pharmaceuticals Headquarter BioNet (Scil?) Pharma R&D International development of protein pharmaceuticals until approval 700 square foot lab space, Gründerzentrum Martinsried 9000 square foot lab- and office-space (6/2000) Halle/Leipzig: Protein Technology Services Founded by Prof. R. Rudolph, Institute for Biotechnology, Halle Small scale production of recombinant proteins (up to 10 g) - samples for pre-clinical research - samples for protein structure analysis/rationale drug design 1000 square foot lab space associated with the Institute for Biotechnology Option for 4200 square foot lab- and office-space (3/2000)

9. scil Scil Pharmaceuticals: Core Management Team CEO U. Martin former head of pharmacology and cardiovascular research at BM/Roche; senior scientist at Hoechst Pre-clinical Research C. Dony Biotechnology U. Kohnert Pharmaceutical Sciences N.N. Non-clinical Development U. Martin Clinical Development M. Beckert Former head of musculoskeletal disorders research at BM/Roche; scientist at Genentech Experienced project leader biotechnology for reteplase, specialist in preformulation at BM/Roche Experienced project leader pre-clinical/ clinical pharma- cology for rete- plase, therap. antibodies, gene therapy Former head of clinical research at MSD Team of legal (B. Jurisch), patent (B. Huber) and diagnostics (A. Wahlefeld) advisors

10. scil Scil Pharmaceuticals: Core Competence Development of protein pharmaceuticals from active compound to approval

11. scil Scil Pharmaceuticals: Core Competence Development of protein pharmaceuticals Protein bulk drug Finished product  Integrated technology platform for bulk drug and finished product - protein process development - formulation/drug delivery - pharmaceutical analyses Pre-clinic bioanalytics Clinical development Regulatory affairs  Experienced steering of non-clinical and clinical development activities including GMP manufacturing via CROs  Team of project leaders with experience in inter- national project development and regulatory filing (FDA & EMEA for RapiLysin ® /Retavase TM ) Approval

12. scil Scil Pharmaceuticals: Fast track development of Anti-L-Selectin (BNP 001) in 1999 Anti-L-selectin for the treatment of multi organ failure (partner: PDL) after polytrauma January 15 February 24 March 31 June 2 June 4 July 14 July 28 September LETTER OF INTENT: PDL - BioNet for anti-L-selectin Start TECHNICAL TRANSFER (know how, reports and materials) CONTRACT PDL - BioNet signed CLINICAL DRUG SUPPLIES released PHASE I: first in man DOSE SELECTION FOR PHASE II Submission of phase II study protocol to CENTRAL ETHICS COMMITTEE of PI PHASE II (Polytrauma): “first patient in”

13. scil Scil Pharmaceuticals: Strategic Focus Antibody/protease technologies  Inflammation / immundisorders  Oncology  Cardiovascular Tissue regeneration technologies, growth factors  Skin disorders / wound healing  Dental disorders / orthopaedics

14. scil Scil Pharmaceuticals: Research & Development Pipeline Antibody/protease technologies Anti-L-selectin  multi organ failure, polytrauma - clinical phase II, 10/99 - market entry 2002 -Kristallin technology (research stage collaboration Prof. R. Rudolph)  Tissue regeneration technologies Anti-neurodermitis treatment (collaboration Prof. R. Rudolph) - clinical phase I Growth factor delivery system, dental application (pre-clinical)

15. scil Scil Proteins Halle: Mission Founded by Prof. R. Rudolph, Institute for Biotechnology, Halle Technology Services, Small scale production of recombinant proteins  samples for pre-clinical research  samples for protein structure analysis, rationale drug design 1000 square foot lab space associated with the Institute for Biotechnology Option for 4200 square foot lab- and office-space (3/2000)

16. scil Scil Proteins Halle: Core Competence Customized folding Expression systems (pro- and eukaryotic organisms) Fermentation facilities: 10 l-, 50 l-, 100 l-reactors (E. coli) Highly specialized protein refolding technology - automatic protein folding reactor for proteins expressed in inclusion bodies (E. coli) Proteinpurification: conventional methods and affinity techniques to guarantee straight forward purification of protein samples Physicochemical characterized and proteinprofiling, mass spectroscopy, CD, fluorescence/biacore, protein sequencing, etc.

17. scil Scil Proteins: Projects of the Institute of Protein Technologies: Prof. R. Rudolph, Halle Successful refolding of inclusion body proteins expressed in E. coli Protein GLP1-Receptor pro NGF pro BMP2 PTH-Receptor Proteinase K Enterokinase Pepsinogen Procollagen C Proteinase h Phosphodiesterase PDE 4 HIV Protease Antibody fragments CD 4 Helicase Partnership Boehringer Mannheim Roche Genetics Institute Schweizer Rotes Kreuz / Novartis Pfizer University Leipzig / AWD University Halle -